507 related articles for article (PubMed ID: 34255907)
21. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19.
Dallalzadeh LO; Ozzello DJ; Liu CY; Kikkawa DO; Korn BS
Orbit; 2022 Oct; 41(5):616-619. PubMed ID: 33752571
[TBL] [Abstract][Full Text] [Related]
22. Rhino-orbital-cerebral-mucormycosis in COVID-19: A systematic review.
Bhattacharyya A; Sarma P; Sharma DJ; Das KK; Kaur H; Prajapat M; Kumar S; Bansal S; Prakash A; Avti P; Thota P; Reddy DH; Gautam BS; Medhi B
Indian J Pharmacol; 2021; 53(4):317-327. PubMed ID: 34414911
[TBL] [Abstract][Full Text] [Related]
23. "Black fungus": a perspective on the coronavirus disease 2019 (COVID-19)-associated rhino-orbital mucormycosis epidemic in India.
Thakar A; Lal D
Int Forum Allergy Rhinol; 2021 Aug; 11(8):1278-1279. PubMed ID: 34185968
[No Abstract] [Full Text] [Related]
24. Mucormycosis as SARS-CoV2 sequelae in kidney transplant recipients: a single-center experience from India.
Meshram HS; Kute VB; Chauhan S; Dave R; Patel H; Banerjee S; Desai S; Kumar D; Navadiya V; Mishra V
Int Urol Nephrol; 2022 Jul; 54(7):1693-1703. PubMed ID: 34792722
[TBL] [Abstract][Full Text] [Related]
25. Results from a national survey on COVID-19-associated mucormycosis in Germany: 13 patients from six tertiary hospitals.
Seidel D; Simon M; Sprute R; Lubnow M; Evert K; Speer C; Seeßle J; Khatamzas E; Merle U; Behrens C; Blau IW; Enghard P; Haas CS; Steinmann J; Kurzai O; Cornely OA
Mycoses; 2022 Jan; 65(1):103-109. PubMed ID: 34655486
[TBL] [Abstract][Full Text] [Related]
26. Coronavirus disease-associated mucormycosis (CAM): A case control study during the outbreak in India.
Wasiq M; K R; Gn A
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443518
[TBL] [Abstract][Full Text] [Related]
27. Mucormycosis in COVID-19 pandemic: study at tertiary hospital in India.
Chavan RP; Ingole SM; Nazir HA; Desai WV; Kanchewad GS
Eur Arch Otorhinolaryngol; 2022 Jun; 279(6):3201-3210. PubMed ID: 35122509
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology, clinical presentation and management of COVID-19 associated mucormycosis: A single centre experience from Pune, Western India.
Dravid A; Kashiva R; Khan Z; Bande B; Memon D; Kodre A; Mane M; Pawar V; Patil D; Kalyani S; Raut P; Bapte M; Saldanha C; Chandak D; Patil T; Reddy S; Bhayani K; Suresh L; Dillibabu V; Srivastava S; Khandelwal S; More S; Shakeel A; Pawar M; Nande P; Harshe A; Kadam S; Hallikar S; Kamal N; Andrabi D; Bodhale S; Raut A; Chandrashekhar S; Raman C; Mahajan U; Joshi G; Mane D
Mycoses; 2022 May; 65(5):526-540. PubMed ID: 35212032
[TBL] [Abstract][Full Text] [Related]
29. Diabetes mellitus and Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): A wake-up call from Egypt.
Alfishawy M; Elbendary A; Younes A; Negm A; Hassan WS; Osman SH; Nassar M; Elanany MG
Diabetes Metab Syndr; 2021; 15(5):102195. PubMed ID: 34314921
[No Abstract] [Full Text] [Related]
30. Oral mucormycosis associated with COVID-19 and diabetes mellitus: Case report and literature review.
Velasco JC; Vargas LJ; García L; Torres IJ; González IC
Biomedica; 2024 Mar; 44(1):10-15. PubMed ID: 38648346
[TBL] [Abstract][Full Text] [Related]
31. COVID-19-associated mucormycosis in India: Why such an outbreak?
Pasquier G
J Mycol Med; 2023 Aug; 33(3):101393. PubMed ID: 37182234
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological association of mucormycosis in COVID 19 pandemic.
Varshney M; Saxena A; Binnani N; Kumar V; Vyas SP
Indian J Pathol Microbiol; 2023; 66(1):101-105. PubMed ID: 36656219
[TBL] [Abstract][Full Text] [Related]
33. A systematic review on SARS-CoV-2-associated fungal coinfections.
Soni S; Namdeo Pudake R; Jain U; Chauhan N
J Med Virol; 2022 Jan; 94(1):99-109. PubMed ID: 34570905
[TBL] [Abstract][Full Text] [Related]
34. COVID-19-associated Mucormycosis: A clinico-epidemiological study.
Chakravarty J; Gupta MK; Tilak R; Kumar R; Maurya RP; Kumar N; Aggarwal SK; S S; Sharma NK; Dhiman NK; Chaubey M; Singh V; Verma A; Banerjee T; Agrawal NK; Prasad RS
J Diabetes Complications; 2022 Sep; 36(9):108284. PubMed ID: 35987108
[TBL] [Abstract][Full Text] [Related]
35. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum.
Sharma S; Grover M; Bhargava S; Samdani S; Kataria T
J Laryngol Otol; 2021 May; 135(5):442-447. PubMed ID: 33827722
[TBL] [Abstract][Full Text] [Related]
36. Epidemiology, Risk Factors, Diagnosis and Treatment of Mucormycosis (Black Fungus): A Review.
Upadhayay P; Bansal K; Goyal A
Curr Pharm Biotechnol; 2023; 24(13):1645-1656. PubMed ID: 36941816
[TBL] [Abstract][Full Text] [Related]
37. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India.
Patel A; Kaur H; Xess I; Michael JS; Savio J; Rudramurthy S; Singh R; Shastri P; Umabala P; Sardana R; Kindo A; Capoor MR; Mohan S; Muthu V; Agarwal R; Chakrabarti A
Clin Microbiol Infect; 2020 Jul; 26(7):944.e9-944.e15. PubMed ID: 31811914
[TBL] [Abstract][Full Text] [Related]
38. Black fungus immunosuppressive epidemic with Covid-19 associated mucormycosis (zygomycosis): a clinical and diagnostic perspective from India.
Singh K; Kumar S; Shastri S; Sudershan A; Mansotra V
Immunogenetics; 2022 Apr; 74(2):197-206. PubMed ID: 34596728
[TBL] [Abstract][Full Text] [Related]
39. COVID-19 and mucormycosis syndemic: double health threat to a collapsing healthcare system in India.
Rocha ICN; Hasan MM; Goyal S; Patel T; Jain S; Ghosh A; Cedeño TDD
Trop Med Int Health; 2021 Sep; 26(9):1016-1018. PubMed ID: 34117677
[TBL] [Abstract][Full Text] [Related]
40. COVID-19-Associated mucormycosis: Case series from a tertiary care hospital in South India.
Rashbi K S; Ali TMF; P N D; C K S; Payyappilly RJ
Access Microbiol; 2022 Aug; 4(6):acmi000360. PubMed ID: 36004359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
